Cell Free DNA (Cfdna) Blood Assays for the Detection of EGFR and Other Clinically Relevant Gene Mutations in Patients with Non-Small Cell Lung Cancer
About this study
The objective of this study is to validate internally developed assays for the detection of clinically relevant gene mutations in cfDNA from the peripheral blood of patients with non-small cell lung carcinoma.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.See eligibility criteria
- age 18 years or older
- histologic evidence of non-small cell lung carcinoma
- immediate plans for a clinically directed tumor biopsy to determine EGFR mutation status
- new diagnosis of advanced or metastatic disease or recent progression on systemic therapy for advanced or metastatic disease
- the absence of an active second active malignancy
- an understanding of the protocol and its requirements, risks, and discomforts
- the ability and willingness to sign an informed consent
- pregnancy or lactation (for females). Pregnancy and lactation will affect cfDNA quality relative to the evaluation of tumor specific alterations.
- "Pregnancy (by self-report of pregnancy status)"
- inability on the part of the patient to understand the informed consent or be compliant with the protocol
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
|Mayo Clinic Location
Mayo Clinic principal investigator
Minetta Liu, M.D.
Open for enrollment
Cassandra Nelson C.C.R.C.